ÂÜÀòÂÒÂ×

Thomas Hardy, MD, PhD is Vice President of Drug Safety and Pharmacovigilance at Immunovant.

Prior to joining Immunovant, Dr. Hardy spent 18 years at Eli Lilly and Company, holding key roles in all phases of Clinical Development. While in Early Phase Medicine at Lilly, Tom oversaw numerous IND filings and directed the design and implementation of over 30 phase 1 and 2 clinical trials of small and large molecule investigational agents across multiple disease areas. He subsequently directed the global registration trials and regulatory filings for late-phase assets in the Diabetes Business Unit, resulting in the global approvals of Baqsimi® and Lyumjev®. Before joining Lilly, he ran a busy clinical practice in Endocrinology.

He holds a B.A. in Biology from the University of California, Santa Cruz and an M.D. and Ph.D. (Biochemistry) from Indiana University. He completed fellowship training in Diabetes, Endocrinology and Metabolism at Vanderbilt University Medical Center.